XPNPEP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30906723	0.76	5/20
SCHEMBL30906755	0.60	5/20
SCHEMBL30906713	0.56	5/20
SCHEMBL30906718	0.52	5/20
SCHEMBL30906756	0.52	5/20
SCHEMBL30906747	1.00	4/20
SCHEMBL30906732	0.76	4/20
SCHEMBL30906715	0.58	4/20
SCHEMBL30906730	0.56	4/20
SCHEMBL30906716	0.54	4/20
SCHEMBL31061617	0.54	4/20
SCHEMBL30906745	0.51	4/20
SCHEMBL30906739	0.50	4/20
SCHEMBL30906754	0.48	4/20
SCHEMBL30906731	0.48	4/20
SCHEMBL30906719	1.00	3/20
SCHEMBL30906733	1.00	3/20
SCHEMBL30906711	0.67	3/20
SCHEMBL30906752	0.66	3/20
SCHEMBL30906700	0.62	3/20

Clinical trials — most relevant to XPNPEP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function	PHASE4	COMPLETED
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults	PHASE3	COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	PHASE2/PHASE3	COMPLETED
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	PHASE3	COMPLETED
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)	PHASE2	UNKNOWN
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency	PHASE2	COMPLETED
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency	EARLY_PHASE1	COMPLETED
Calcitonin for Treating X-linked Hypophosphatemia	nan	COMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum	nan	COMPLETED
Genetic Studies of X-linked Lymphoproliferative Disease	nan	COMPLETED
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy	nan	COMPLETED
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
The PORTRAIT Study	nan	UNKNOWN
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners	nan	ACTIVE_NOT_RECRUITING
Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)	nan	COMPLETED
Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin	nan	UNKNOWN
Developing a Management Approach for Patients With Late-Onset Pompe Disease	nan	ACTIVE_NOT_RECRUITING
PCD New Gene Discovery	nan	COMPLETED
Molecular Associations With Reproductive Failure	nan	COMPLETED
Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis	nan	COMPLETED
Genetic Response to Warfarin in Healthy Subjects	nan	COMPLETED
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study	nan	RECRUITING
Genetics of Ehlers-Danlos Syndrome	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a XPNPEP1 binder may also engage these)

Protein	Name	Similarity
Q1JPJ2	—	0.997	Q1JPJ2 →
Q6P1B1	—	0.996	Q6P1B1 →
O54975	—	0.996	O54975 →
B0DZL3	—	0.993	B0DZL3 →
C5G874	—	0.992	C5G874 →
D5GAC6	—	0.990	D5GAC6 →
E9CTR7	—	0.990	E9CTR7 →
B2VUU7	—	0.989	B2VUU7 →
Q9VJG0	—	0.989	Q9VJG0 →
E9E9B2	—	0.989	E9E9B2 →
E9EUE6	—	0.989	E9EUE6 →
Q09795	—	0.988	Q09795 →
Q0CDB3	—	0.988	Q0CDB3 →
E3QCU0	—	0.988	E3QCU0 →
C0NDZ7	—	0.987	C0NDZ7 →
B8M9W2	—	0.987	B8M9W2 →
A2QGR5	—	0.987	A2QGR5 →
B0Y3V7	—	0.987	B0Y3V7 →
B6QG01	—	0.987	B6QG01 →
A7E4T8	—	0.986	A7E4T8 →
C5GXZ9	—	0.986	C5GXZ9 →
A1CAQ1	—	0.986	A1CAQ1 →
A6RK67	—	0.986	A6RK67 →
A6R035	—	0.986	A6R035 →
C9SR45	—	0.986	C9SR45 →
C0SCV1	—	0.985	C0SCV1 →
C6HSY3	—	0.985	C6HSY3 →
C4JF09	—	0.985	C4JF09 →
F4JQH3	—	0.985	F4JQH3 →
C6H7R7	—	0.985	C6H7R7 →